Evidence map›Paper›PMID 41828713›Full record

ArticleInternational journal of molecular sciences2026

Jane Tchekalarova, Petj Ivanova, Violina T Angelova, Nicol Bogdanova, Stanislav Bozhanov, Miglena Smerikarova, Vania Maslarska

Abstract read
In one paragraph

Article in International journal of molecular sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Jane TchekalarovaInstitute of Neurobiology, Bulgarian Academy of Sciences, 1000 Sofia, Bulgaria.ORCID 0000-0003-1640-5099
Petj IvanovaInstitute of Neurobiology, Bulgarian Academy of Sciences, 1000 Sofia, Bulgaria.
Violina T AngelovaDepartment of Chemistry, Faculty of Pharmacy, Medical University-Sofia, 1431 Sofia, Bulgaria.
Nicol BogdanovaInstitute of Neurobiology, Bulgarian Academy of Sciences, 1000 Sofia, Bulgaria.
Stanislav BozhanovDepartment of Chemistry, Faculty of Pharmacy, Medical University-Sofia, 1431 Sofia, Bulgaria.
Miglena SmerikarovaDepartment of Chemistry, Faculty of Pharmacy, Medical University-Sofia, 1431 Sofia, Bulgaria.
Vania MaslarskaDepartment of Chemistry, Faculty of Pharmacy, Medical University-Sofia, 1431 Sofia, Bulgaria.

Funding

"Strategic Research and Development Innovation Program of Medical University-Sofia" BG-RRP-2.004-0004-C01
6 · The paper itself

Abstract

The pathogenesis of Parkinson's disease (PD) is characterized by progressive degeneration of nigrostriatal dopaminergic signaling, resulting in motor dysfunction. Although monoamine oxidase (MAO) inhibitors are clinically used in PD, their long-term efficacy and safety remain limited. In the present study, three novel N-benzylpyrrolidine derivatives (

Indexed as

Monoamine OxidaseMonoamine Oxidase InhibitorsParkinson DiseasePyrrolidines1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridineAnimalsCorpus StriatumDisease Models, AnimalDopamineMaleMiceMice, Inbred C57BL1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridineDopamineMonoamine OxidaseMonoamine Oxidase InhibitorsPyrrolidinesdopamineinflammationMAO-B inhibitormicemotor dysfunctionMPTPParkinson’s disease

Identifiers

PMID41828713
PMCPMC12985612

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.